Innovative Therapeutics in Oncology and Neuroscience

43 • . NUZYRA FDA-and China NMPA-approved, Once-Daily Oral and IV Broad Spectrum Antibiotic Addressing Antibiotic Resistance Clinical Per-protocol Population Investigator-assessed Clinical Response at Post Therapy Evaluation¹ Clinical Per-protocol Population Investigator-assessed Clinical Response at Post Therapy Evaluation² Approved NDC 71715-001-01 NUZYRA (omadacycline) for in 100 mg/vial single-dose vial For intravenous infusion Dambuted by on MA-0056 CABP NUZYRAⓇ (omadacycline) 150 OMC New differentiated tetracycline antibiotic Clinical success in CABP (left) and ABSSSI (right) Category 1 Innovative Drug in China % of Population ABSSSI 93% 90% 96% 94% 100 100 80 60 40 20 0 NUZYRA (n=316/340) MOXIFLOXACIN (n=312/345) Difference 95% CI, 2.5 (-1.7, 6.8) % of Population NA g ∞ 20 80 60 40 0 NUZYRA (n=259/269) LINEZOLID (n=243/260) Difference 95% CI, 2.8 (-1.0, 6.9) Commercial launch in December 2021; Successful NRDL inclusion for both IV and oral formulations on Jan 1st, 2024 Sources: Paratek corporate presentation, February 2021; NUZYRA Prescribing Information, Paratek Pharmaceuticals, Inc; Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med 2019;380:517-27; O'Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med 2019;380:528-38. Notes: (1) 5-10 days after last dose; (2) 7-14 days after last dose. Clinical Data - Anti-infective

View entire presentation